13 October 2023 in Nucleic Acids Research
Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which, via their antibody (mAb) component, deliver and release their potent warhead (a.k.a. payload) at the disease site, thereby simultaneously improving the efficacy of delivered therapy and reducing its off-target toxicity. To design ADCs of promising efficacy, it is crucial to have the critical data of pharma-information and biological activities for each ADC. However, no such database has been constructed yet. In this study, a database named ADCdb focusing on providing ADC information (especially its pharma-information and biological activities) from multiple perspectives was thus developed. Particularly, a total of 6572 ADCs (359 approved by FDA or in clinical trial pipeline, 501 in preclinical test, 819 with in-vivo testing data, 1868 with cell line/target testing data, 3025 without in-vivo/cell line/target testing data) together with their explicit pharma-information was collected and provided. Moreover, a total of 9171 literature-reported activities were discovered, which were identified from diverse clinical trial pipelines, model organisms, patient/cell-derived xenograft models, etc. Due to the significance of ADCs and their relevant data, this new database was expected to attract broad interests from diverse research fields of current biopharmaceutical drug discovery. The ADCdb is now publicly accessible at: https://idrblab.org/adcdb/.
22 September 2025 in Journal of Medicinal Chemistry
12 July 2024 in Journal of Medicinal Chemistry
1 May 1990 in American Journal of Physiology-Gastrointestinal and Liver Physiology
A biologically active, chemically defined, radioactive ligand was used for characterizing bombesin (BBS) receptors on rat pancreatic acinar cancer cells (AR42J). [Tyr4]BBS, iodinated with enzymobeads and fractionated by high-performance liquid chromatography, was monitored for biological activity as evidenced by gastrin release from perfused isolated rat stomach. The monoiodinated peptide peak was greater than 95% biologically active, with a specific activity of greater than 2,000 disintegrations.min-1.fmol-1. The maximum number of BBS receptors per cell were measured at 30 degrees C after 20-25 min of incubation; binding was submaximum at temperatures lower or higher than 30 degrees C. A single class of high-affinity binding sites (Kd = 1.77 +/- 0.21 nM) was identified for BBS on AR42J cells and nonspecific binding was less than 20-30% at all points. A total of 1.47 +/- 0.14 x 10(5) specific BBS binding sites per cell were measured that were specific for BBS and gastrin-releasing peptide (GRP) analogues. Iodinated GRP-(1-27) was cross-linked to BBS receptors on AR42J cells using several bifunctional cross-linking reagents followed by polyacrylamide gel electrophoresis of the solubilized receptor complex under reducing and nonreducing conditions. A densitometric analysis of the autoradiographs demonstrated the presence of an approximately 80- to 85-kDa molecular form of the receptor as a major component under both reducing and nonreducing conditions. These results indicated that the receptor molecule is a single subunit without multiple chains covalently attached by disulfide bonding.
20 November 2026 in Nucleic Acids Research
Systematically characterizing antibody-drug conjugates (ADCs) is essential for understanding their therapeutic properties, guiding molecular design, and supporting clinical development. Recently, the expanding clinical landscape of ADCs has generated extensive information on target antigens, therapeutic indications, and clinical trial pipelines, providing a valuable foundation for informing ADC development strategies. Moreover, ADMET profiles are critical for understanding the in vivo disposition, efficacy, and safety of ADCs. Integrating these accumulating clinical and pharmacological data is therefore necessary to enrich the evidence available for ADC development. In this study, ADCdb was updated to provide (i) detailed clinical landscape information for 542 ADCs, together with >3000 manually curated clinical trials from registries across nine registries and clinical trial platforms; (ii) >4000 ADMET profiles, including quantitative pharmacokinetic parameters and descriptive annotations supported by relevant references; and (iii) expanded pharmacological information and biological activity data comprising 13 088 ADC entries and 24 821 activity records, as well as ADC-specific functional annotations for 389 ADCs. Interactive visualization tools and antigen- and disease-centered search modules further enable systematic exploration of ADC composition, therapeutic indications, and clinical development. ADCdb 2.0 is expected to serve as a valuable resource for rational optimization of ADCs, and is accessible at https://idrblab.org/adcdb/